Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award

Rhea-AI Summary

Agilent Technologies (NYSE: A) announced the Altura Ultra Inert HPLC columns, a new product line aimed at biotherapeutics analysis including peptide GLP-1 and oligonucleotide workflows. The release highlights faster conditioning, improved peak shape, enhanced sensitivity, and a fully inert sample flow path designed for demanding QC and development labs.

Agilent claims up to 2x sensitivity, 3x signal-to-noise ratio, and, when paired with the Agilent 1290 Infinity III Bio LC, up to 30x higher peak area; an external test cited a ~30% sensitivity increase and reduced peak tailing on acidic peptides.

Positive

• Up to 2x sensitivity versus competitor columns
• 3x signal-to-noise ratio improvement claimed versus competitors
• Up to 30x higher peak area when paired with Agilent 1290 Infinity III Bio LC
• ~30% sensitivity increase and reduced peak tailing reported for GLP-1 peptide analysis

Negative

• None.

Insights

Analytical Instruments Strategist

Agilent launched the Altura Ultra Inert HPLC columns claiming material sensitivity and chromatographic gains for biotherapeutics workflows.

Agilent expands its LC column portfolio with the Altura Ultra Inert line aimed at peptide and oligonucleotide analysis, positioning the product as a higher‑performance stationary phase that reduces analyte-surface interactions and improves peak shape and sensitivity.

The business mechanism is straightforward: better column inertness and chemistry can reduce signal loss and tailing, which directly improves detection limits and assay robustness for challenging analytes such as GLP‑1 peptides and acidic oligonucleotides. The stated performance uplifts — up to 2x sensitivity, 3x signal‑to‑noise, and claims of up to 30x higher peak area when paired with Agilent instrumentation — if realized, would shorten method development time and lower the risk of failed impurity characterization.

Key dependencies and risks include real‑world reproducibility across customer labs, compatibility with existing workflows, and independent verification of the vendor performance claims. Customer testimonial data (a 30 sensitivity gain cited) helps but does not substitute for broad, blinded comparability studies. Monitor third‑party validation reports, application notes detailing method conditions, and product adoption signals over the next 12 months to assess whether the claimed benefits translate into measurable lab productivity and revenue uplift.

PONTE VEDRA, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced its Chairman and Chief Executive Officer, Quang X. Pham, received the prestigious BioFlorida, Inc. “Executive of the Year Award,” at the recently held Florida Innovation Conference, powered by BioFlorida, in Orlando.

As the voice of Florida’s life-science ecosystem, BioFlorida represents biotechnology, medical-technology, digital health and health system organizations across the state and is committed to advancing innovation, economic growth and patient-impacting therapies.

“Our Executive of the Year Award underscores the remarkable leadership and vision that Quang has brought to Cadrenal and to Florida’s biotech sector,” said Mark A. Glickman, CEO of BioFlorida. “He exemplifies the entrepreneurial spirit and patient-centric innovation that our state’s life sciences community stands for.”

Under Pham’s leadership, Cadrenal has uniquely positioned itself to address gaps in anticoagulation treatment of multiple indications through the development of two differentiated anticoagulants (tecarfarin and frunexian). He founded Cadrenal after a distinguished career that includes founding other life-science and digital-health firms, as well as service as a U.S. Marine Corps officer.

“I am deeply honored to receive this recognition from BioFlorida,” said Pham. “BioFlorida has been by our side from day one. Our team is motivated every day by the patients who have few options for safe and effective anticoagulation. This award is a tribute to all of them.”

About Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. is a biopharmaceutical company with a mission to develop novel and differentiated biopharmaceutical products that bridge critical gaps in current acute and chronic anticoagulant therapy. We bridge these gaps by developing novel and differentiated anticoagulants, or blood thinners, designed to provide greater predictability, increased stability, more precise control, and fewer bleeding complications. We currently have two clinical-stage assets: tecarfarin, an oral vitamin K antagonist (VKA) for chronic use, and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. By targeting underserved patient populations and advancing therapies designed for both chronic and acute use, we aim to reshape standards of care in anticoagulation. For more information, visit https://www.cadrenal.com/ and connect with the Company on LinkedIn.

Safe Harbor

Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding developing transformative therapeutics to overcome current gaps in anticoagulation therapy and positioning the Company to address gaps in anticoagulation treatment of multiple indications through the development of two differentiated anticoagulants. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to develop transformative therapeutics to overcome current gaps in anticoagulation therapy, the ability to successfully complete clinical trials on time and achieve desired results and benefits as expected and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information, please contact:

Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com

FAQ

What are the key benefits of Agilent Altura Ultra Inert HPLC columns announced on November 19, 2025?

They target biotherapeutics with claims of faster conditioning, improved peak shape, and up to 2x sensitivity plus 3x signal-to-noise versus competitors.

How do Altura columns improve GLP-1 peptide analysis for labs?

An external user reported about a 30% sensitivity increase and reduced peak tailing for acidic peptides and excipients.

Can Altura columns be used with Agilent 1290 Infinity III Bio LC and what is the claimed effect?

Yes; Agilent claims pairing with the 1290 Infinity III Bio LC can deliver up to 30x higher peak area.

Are Altura HPLC columns designed for oligonucleotide therapeutic development?

Yes; the product line is promoted for peptide and oligonucleotide therapeutic development and quality control workflows.

What proprietary technology do Altura columns use to achieve inertness?

Altura columns use Agilent's proprietary Ultra Inert coating technology to minimize analyte-surface interactions.

Where do Altura columns fit in Agilent's product portfolio for biopharma labs?

They expand Agilent's inert flow path solutions, positioned as a high-performance option for demanding biotherapeutics analysis.